The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin

An Algorithm for the Grading of Activity in Chronic Hepatitis C

Pierre Bédossa, Thierry Poynard · Hepatology · 1996 · 4K citations · Full text

Medicine, Internal Medicine, Pathology +17

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz, Mark Sulkowski, Reem Ghalib et al. · The Lancet · 2014 · 818 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

Jacques Fellay, Alexander Thompson, Dongliang Ge et al. · Nature · 2010 · 441 citations · Full text

Medicine, Genetics, Molecular Genetics +12

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Ira M. Jacobson, Gregory J. Dore, Graham R. Foster et al. · The Lancet · 2014 · 436 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Michael P. Manns, Patrick Marcellin, Fred Poordad et al. · The Lancet · 2014 · 375 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16